StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research note issued to investors on Saturday. The brokerage set a "sell" rating on the stock.

Several other brokerages also recently issued reports on NSPR. Lake Street Capital started coverage on shares of InspireMD in a report on Wednesday, December 11th. They set a "buy" rating and a $5.00 price target for the company. Piper Sandler reissued an "overweight" rating and set a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Price Performance

Shares of NYSE:NSPR traded down $0.18 during trading on Friday, reaching $2.69. 44,967 shares of the company's stock traded hands, compared to its average volume of 29,186. The company has a 50 day moving average of $2.73 and a 200-day moving average of $2.70. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The stock has a market capitalization of $70.17 million, a P/E ratio of -3.59 and a beta of 0.98.

InspireMD (NYSE:NSPR - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The company had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same period in the prior year, the company earned ($0.15) earnings per share. Equities research analysts predict that InspireMD will post -0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in InspireMD, Inc. (NYSE:NSPR - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 104,081 shares of the company's stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned approximately 0.42% of InspireMD at the end of the most recent reporting period. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.